Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families but continues to receive good FDA news regarding its treatment for Alzheimer's Disease. The company announced that it has completed enrollment for the Phase 2b trial evaluating laromestrocel for the treatment of HLHS. The rare nature of the condition makes this a major milestone for the company.